Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score

Mazzaschi, Giulia; Lazzarin, Alessandro; Santoni, Matteo; Trentini, Francesca; Giorgi, Ugo De; Brighi, Nicole; Tommasi, Chiara; Puglisi, Silvia; Caffo, Orazio; Kinspergher, Stefania; Mennitto, Alessia; Cattrini, Carlo; Verzoni, Elena; Rametta, Alessandro; Stellato, Marco; Malgeri, Andrea; Roviello, Giandomenico; Silini, Enrico Maria; Rescigno, Pasquale; Rebuzzi, Sara Elena; Fornarini, Giuseppe; Quaini, Federico; Giudice, Giulia Claire; Banna, Giuseppe Luigi; Buti, Sebastiano

doi:10.31083/j.fbe1503020

Cited by 3 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous study demonstrated the prognostic significance of the red cell-based score incorporating Hb, MCV, and RDW, in patients with mRCC undergoing TKI treatment. Patients carrying at least two favourable prognostic factors experienced notably extended PFS and OS compared to those with 0 to 1 positive prognostic factors [ 23 ]. In the present work, we aimed to validate the red cell-based score in a more actual clinical setting involving a population of patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI).…”

Section: Discussionmentioning

confidence: 99%

“…According to our previous study on patients with mRCC treated with TKIs, MCV > 87 fl (macrocytosis), RDW 16% (anisocytosis) and Hb ≥ 12 g/dL (absence of anaemia) were considered favourable prognostic factors. Based on the number of positive prognostic factors, we divided our patient population into two groups: favourable group (2–3 good factors) and unfavourable (0–1 good factors) [ 23 ].…”

Section: Methodsmentioning

confidence: 99%

“…Focusing on the same population, our group developed a red cell-based score through the integration of Hb, MCV and RDW, and delineated two prognostic groups: unfavourable group (0–1 good factors) and favourable group (2–3 good factors). Irrespective of other established prognostic factors, patients in the favourable group demonstrated significantly longer PFS and OS when compared to those in the unfavourable group [ 23 ]. In addition to the prognostic significance, these studies suggested that Hb, MCV and RDW may serve as an indirect indicators of the activation and alterations of the HIF-1α pathway among patients with mRCC undergoing TKIs [ 24 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations

Maffezzoli,

Santoni,

Mazzaschi

et al. 2024

Clin Exp Metastasis

Self Cite

View full text Add to dashboard Cite

Immunotherapy combinations with tyrosine-kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) had significantly improved outcomes of patients with mRCC. Predictive and prognostic factors are crucial to improve patients’ counseling and management. The present study aimed to externally validate the prognostic value of a previously developed red cell-based score, including hemoglobin (Hb), mean corpuscular volume (MCV) and red cell distribution width (RDW), in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI). We performed a sub-analysis of a multicentre retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations. Uni- and multivariable Cox regression models were used to assess the correlation between the red cell-based score and progression-free survival (PFS), and overall survival (OS). Logistic regression were used to estimate the correlation between the score and the objective response rate (ORR). The prognostic impact of the red cell-based score on PFS and OS was confirmed in the whole population regardless of the immunotherapy combination used [median PFS (mPFS): 17.4 vs 8.2 months, HR 0.66, 95% CI 0.47–0.94; median OS (mOS): 42.0 vs 17.3 months, HR 0.60, 95% CI 0.39–0.92; p < 0.001 for both]. We validated the prognostic significance of the red cell-based score in patients with mRCC treated with first-line immunotherapy combinations. The score is easy to use in daily clinical practice and it might improve patient counselling.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations

Maffezzoli,

Santoni,

Mazzaschi

et al. 2024

Clin Exp Metastasis

Self Cite

View full text Add to dashboard Cite

show abstract

“…According to our previous study on patients with mRCC treated with TKIs, MCV > 87 (macrocytosis), RDW 16% (anisocytosis) and Hb ≥ 12 g/dL (absence of anaemia) were considered favourable prognostic factors. Based on the number of positive prognostic factors, we divided our patient population into two groups: favourable group (2-3 good factors) and unfavourable (0-1 good factors) [23].…”

Section: Methodsmentioning

confidence: 99%

“…Focusing on the same population, our group developed a red cell-based score through the integration of Hb, MCV and RDW, and delineated two prognostic groups: unfavourable group (0-1 good factors) and favourable group (2-3 good factors). Irrespective of other established prognostic factors, patients in the favourable group demonstrated signi cantly longer PFS and OS when compared to those in the unfavourable group [23]. In addition to the prognostic signi cance, these studies suggested that Hb, MCV and RDW may serve as an indirect indicators of the activation and alterations of the HIF-1α pathway among patients with mRCC undergoing TKIs [24].…”

mentioning

confidence: 95%

External Validation of a Red Cell-based Blood Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Treated With First- Line Immunotherapy Combinations

MAFFEZZOLI,

SANTONI,

MAZZASCHI

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Introduction Immunotherapy combinations with tyrosine-kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) had significantly improved outcomes of patients with mRCC. Predictive and prognostic factors are crucial to improve patients' counseling and management. The present study aimed to externally validate the prognostic value of a previously developed red cell-based score, including hemoglobin (Hb), mean corpuscular volume (MCV) and red cell distribution width (RDW), in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI). Materials and methods We performed a sub-analysis of a multicentre retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations. Uni- and multivariable Cox regression models were used to assess the correlation between the red cell-based score and progression-free survival (PFS), and overall survival (OS). Logistic regression were used to estimate the correlation between the score and the objective response rate (ORR). Results. The prognostic impact of the red cell-based score on PFS and OS was confirmed in the whole population regardless of the immunotherapy combination used [median PFS (mPFS): 17.4 vs 8.2 months, HR 0.66, 95% CI 0.47–0.94; median OS (mOS): 42.0 vs 17.3 months, HR 0.60, 95%CI 0.39–0.92; p < 0.001 for both]. Conclusion. We validated the prognostic significance of the red cell-based score in patients with mRCC treated with first-line immunotherapy combinations. The score is easy to use in daily clinical practice and it might improve patient counselling.

show abstract

A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study

Anpalakhan,

Banna,

Rebuzzi

et al. 2024

Immunotherapy

View full text Add to dashboard Cite

Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score

Cited by 3 publications

References 0 publications

External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations

External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations

External Validation of a Red Cell-based Blood Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Treated With First- Line Immunotherapy Combinations

A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study

Contact Info

Product

Resources

About